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Singapore (n=9), Hong Kong (n=6), Thailand (n=6), South Korea (n=6), India (n=5), 
Bangladesh (n=1), and Iran (n=1) (some studies pertain to more than one 
country). The CUAs contained 294 ICERs and 436 utility weights. The median 
ICER for all Asian CUAs was $11,000/QALY. The median ICER for tertiary 
prevention interventions ($9,800/QALY, n=157) was favorable, compared to the 
ICERs for primary and secondary prevention interventions ($22,000/QALY, n=69 
and $33,000/QALY, n=62); (p<0.005). The median ICER for immunizations was 
most favorable ($2,300/QALY, n=33), followed by surgical interventions, 
diagnostic interventions and pharmaceuticals and medical devices. In contrast, 
screening programs reported the least favorable ratios ($37,000/QALY, n=90). 
Studies examining infectious diseases had a lower median ICER ($8,500/QALY, 
n=43), compared to ICERs for interventions for cardiovascular diseases and 
cancer. CONCLUSIONS: Over 100 English-language CUAs targeted toward Asian 
countries have been published in English-language journals in recent years. 
Compared to interventions for primary and secondary prevention, interventions 
targeted towards treatments were relatively cost-effective. ICERs for screening 
programs have been relatively cost-ineffective.  
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OBJECTIVES: To evaluate the quality of published cost-effectiveness analyses of 
biologic disease modifying antirheumatic drugs (bDMARDs) for rheumatoid 
arthritis (RA), and to identify methodological issues that can explain the 
discrepancies in the findings of these cost-effectiveness analyses. METHODS: We 
performed a systematic literature review to identify cost-effectiveness analyses 
of biologics indicated for RA. We compared the incremental the cost-
effectiveness ratios (ICERs), the net health benefits (NHB), the net monitory 
benefits (NMB), cost-effectiveness acceptability curves (CEACs), and cost-
effectiveness frontiers. RESULTS: We observed large discrepancies, which were 
predominantly due to the use of different information sources on the 
effectiveness of the considered biologics. First, substantial differences were 
observed in the ICER, NHB, NMB estimates. When considering the uncertainty 
associated with the NHB and NMB estimates, i.e. their 95% confidence intervals, 
differences were still apparent. CEACs and cost-effectiveness frontiers were only 
reported in a sub-set of the identified publications. Reading from the CEACs and 
cost-effective frontier graphs, fixed willingness to pay thresholds yielded 
different probabilities of the considered biologics being cost-effective. 
CONCLUSIONS: Cost-effectiveness analyses of biologics indicated for RA need to 
carefully consider the source of information used as model inputs. Future cost-
effectiveness analyses need to assess the large number of evidence synthesis 
studies conducted on the relative effectiveness of biologics when determining 
the appropriate model inputs.  
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OBJECTIVES: There is some disagreement in the literature as to whether analysts 
should include all “future” costs or make distinctions between related and 
unrelated medical costs. Most guidelines lack definitive recommendations and 
urge analysts to use discretion or to employ sensitivity analysis to show how 
different approaches influence results. This study evaluated cost methods used 
in the published literature and evaluated the impact on cost-effectiveness of 
including different cost categories. METHODS: Systematic review included cost-
utility analyses from the Tufts CEA Registry published since 2000. We included 
cancer intervention studies where the intervention extended life expectancy. We 
identified specific types of costs included, and whether they varied by study 
characteristics such as cancer type, intervention type, country, perspective, 
conclusions. Further, we estimated alternative incremental cost-effectiveness 
ratios (ICERs) in which the ratio reflected different cost categories, including net 
costs due to study intervention, related medical costs of the treated condition, 
and unrelated medical costs. RESULTS: Of the 59 studies reviewed, none 
included medical costs unrelated to the treated condition, and 14 studies (24%) 
excluded direct medical costs related to the condition but not the evaluated 
intervention. Most studies assumed a health care payer perspective, included 
pharmaceutical interventions and reported ratios below $50,000/QALY. A greater 
proportion of government than industry studies included nonmedical costs. 
Recomputing ICERs by eliminating medical costs not affected by the evaluated 
intervention made 26 additional ratios (68%) cost-saving and 4 more ratios (11%) 
cost-effective. Recomputing ICERs by including unrelated medical costs made 6 
fewer ratios (10%) cost-saving and 4 fewer ratios (7%) cost-effective. 
CONCLUSIONS: Conventional CE methods may implicitly penalize therapies that 
add “expensive” life years for chronically ill patients. Presenting ICERs computed 
with and without disease-attributable costs can help better convey how much 
the treatment itself contributes to overall costs. Inclusion of unrelated medical 
costs affects ICERs less strongly.  
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OBJECTIVES: To determine study quality, estimate quality scoring reliability, and 
assess theorized quality predictors of pharmacoeconomic publications 
evaluating recent new molecular entity and biologic license approvals (NMEs) by 
the Food and Drug Administration (FDA). METHODS: Original 
pharmacoeconomic studies (cost-effectiveness, cost-utility, cost-benefit or cost-
minimization) considering any of 50 NMEs approved in 2008-09 and published on 
or before December 31, 2011 were eligible. MEDLINE and the UK National Health 
Service Economic Evaluation Database were searched. Quality was scored with 
the Quality of Health Economic Studies (QHES) instrument for each publication 
by one primary and two secondary reviewers. Interrater reliability was assessed 
using Pearson correlations of QHES scores. Regression was performed of QHES 
score on study characteristics including number of authors, journal impact factor 
one-year pre-submission, journal type (disease-specific/general clinical/health 
economic), NME FDA review classifications (priority/standard and orphan/non), 
publication timing (pre-/post-NME approval), author(s) having academic 
affiliation (yes/no), advanced modeling PE techniques (yes/no), United States 
study (yes/no), data (primary/secondary), incorporation of quality-adjusted life 
years (yes/no), and conclusion (favorable/unfavorable for NME). RESULTS: The 
literature search yielded 203 search results with 37 publications meeting 
inclusion criteria, encompassing 38% of the 2008-09 NMEs. Averaging all 
reviewers, the QHES score range was 15-92, with a median 70, and mean 
68.4±18.4. The total QHES score was significantly correlated between reviewers 
(R= 0.677). A square transformation was applied to QHES score to correct for a 
negatively skewed distribution. Regression analyses were non-significant for all 
study characteristics, although use of advanced modeling PE techniques 
approached significance (p=0.083). CONCLUSIONS: QHES scores indicated that 
the quality of pharmacoeconomic literature for newly-approved NMEs varies, 
although the 51.3%, 19, highest scoring studies (including and above the median) 
were near or exceeded the 75 point threshold considered “good”. Interrater 
reliability for QHES assessment was fair. Sample size was insufficient to identify 
significant predictors among the variables analyzed.  
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OBJECTIVES: To evaluate the extent and quality of published 
pharmacoeconomics studies based in China. METHODS: A systematic literature 
search was conducted using PubMed, Web of Science, and Google Scholar to 
identify pharmacoeconomics studies conducted in China. The keywords 
included different combinations of the following: health economics, 
pharmacoeconomics, cost-effectiveness, and China. The inclusion criteria for the 
studies were as follows: 1) original research articles; 2) written in English; 3) 
compared a pharmaceutical to another pharmaceutical, treatment modality, or 
no treatment; and 4) conducted in China. The articles were reviewed by two 
independent reviewers using the 100- point Quality of Health Economic Studies 
(QHES) scale for pharmacoeconomic studies and a subjective 10-point scale for 
cost studies. Disagreements were settled by a third researcher. General and 
economic analysis information of the articles was collected. RESULTS: A total of 
19 studies were included. The studies were published in 11 different journals 
between 2006 and 2012 with an average of five authors (SD=2.5). The mean QHES 
scores for the 17 pharmacoeconomic studies was 80.4 (SD=9.9) and the mean 
quality score for the two cost studies was 7.0 (SD=0.7). More than two-thirds of 
the authors resided in China (68.4%) and most of them had a medical 
background (89.5%). Most studies were published in journals based in foreign 
countries (not China) (89.5%) and used modeling as their study design (80.0%). 
Articles published in foreign journals had a higher quality score but the 
difference was not significant (80.5 ± 9.7 vs 69.0 ± 8.5). CONCLUSIONS: China-
based pharmacoeconomics studies written in English are limited, but on average, 
are of good quality. Economic evaluation of pharmaceuticals should be 
encouraged in China because appropriate allocation of health care resources is 
important in a country with large unmet medical needs.  
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OBJECTIVES: The recently made coverage decisions by the UK's NICE, Scotland's 
SMC and the allocation of $1.1 billion for comparative effectiveness research by 
the U.S. are strong indicators of trends in pricing and reimbursement that are 
likely to be observed in the future. To gain an additional insight into these 
trends, we analyzed the cost effectiveness studies for the top twenty highest 
selling drugs (~$90-100B worldwide sales). METHODS: The Top 20 drugs were 
selected based on their worldwide sales. For this analysis, we segmented these 
drugs into categories such as primary care, specialty, small molecules, biologics, 
therapy areas, and availability of generic alternatives. We analyzed the cost 
effectiveness studies that were published in peer-reviewed journals. Searches 
were conducted using generic names of the drugs and the phrase “cost 
effectiveness” in an abstract of the published study. RESULTS: Between 2007-
2012, the number of published studies on “cost effectiveness” has increased by 
more than 32%. There is a large variability in CERs for same drugs for different 
indications, in some cases also varying by biomarkers. Primary care drugs had 
lower and less variable CERs than specialty drugs. Variations also exist in 
methodology used by different groups in modeling cost effectiveness, especially 
for time horizon and comparator. The majority of primary care drugs were 
